Drug Profile
Atropine sulphate ophthalmic - Santen Pharmaceutical
Alternative Names: DE 127; STN-10127; STN-1012700Latest Information Update: 25 Aug 2022
Price :
$50
*
At a glance
- Originator Nanyang Technological University; SingHealth
- Developer Santen Pharmaceutical
- Class Alkaloids; Antidotes; Cardiovascular therapies; Eye disorder therapies; Small molecules; Tropanes
- Mechanism of Action Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Myopia
Most Recent Events
- 01 Jun 2022 Phase-II/III clinical trials in Myopia in China (Ophthalmic) (Santen Pharmaceutical pipeline, August 2022)
- 01 Sep 2021 Phase-I clinical trials in Myopia in China (Ophthalmic) (Santen Pharmaceutical pipeline, January 2022)
- 09 Apr 2020 Santen Pharmaceuticals completes the phase II trial in Myopia (In Children) in Singapore (Opthalmic) in April 2020 (NCT03329638)